Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Dose Response Curve: Conventional Versus Nonmonotonic

Dose Response Curve: Conventional Versus Nonmonotonic

The correlation between a drug's dosage and its impact on a biological system is a cornerstone of pharmacology and toxicology. Conventional dose–response curves, which include graded and quantal relationships, are key to this understanding. Graded dose–response curves depict the spectrum of a biological reaction to different doses within an individual, indicating that as the drug dosage increases, so does the intensity of the response. On the other hand, quantal dose–response relationships...

Bioequivalence Experimental Study Designs: Repeated Measures, Cross-Over, Carry-Over, and Latin Square Designs

Bioequivalence Experimental Study Designs: Repeated Measures, Cross-Over, Carry-Over, and Latin Square Designs

Bioequivalence experimental study designs play a pivotal role in testing the effectiveness of various treatments. Key among these are the repeated measures, cross-over, carry-over, and Latin square designs. In the repeated measures design, each subject receives all treatments, allowing for temporal comparisons. This type of design is useful in reducing variability but requires careful planning to avoid bias.The cross-over design, an economical method, involves sequential administration of...

Dose-Response Relationship: Overview

Dose-Response Relationship: Overview

Agonists can bind with and activate receptors, resulting in the formation of drug-receptor complexes. Once formed, these complexes catalyze many biochemical processes at the cellular level and subsequently induce a pharmacologic response. The degree of response is directly proportional to the fraction of activated receptors, which in turn, depends on the concentration of the drug at the receptor site as well as the sensitivity of the receptor. An increase in the administered dose contributes to...

Dose-Response Relationship: Selectivity and Specificity

Dose-Response Relationship: Selectivity and Specificity

Drugs exert their therapeutic effects by interacting with receptors, enzymes, or ion channels that are present throughout the human body. The strength and duration of the interaction between a drug and its target receptor are characterized by the selectivity and specificity of the drug. Selectivity refers to a drug's strong preference for its intended target over other targets. For instance, isoprenaline, a non-selective β-adrenergic agonist, interacts with both β1- and β2-adrenergic receptors...

Dose-Response Relationship: Potency and Efficacy

Dose-Response Relationship: Potency and Efficacy

The potency of a drug is the measure of its ability to produce a biological response and can be compared by looking at the half-maximum effective concentration or EC50 values of different drugs. A lower EC50 value indicates higher potency of the drug. In the dose–response curve of two antihypertensive drugs, candesartan and irbesartan, a significant difference is observed in their EC50 values. A lower EC50 value for candesartan indicates that it is more potent than irbesartan, as it produces...

Dosage Regimens: Designs and Approaches

Dosage Regimens: Designs and Approaches

Designing a dosage regimen, which refers to the manner of drug administration, is a complex process involving the selection of drug dose, route, and frequency. This process is underpinned by pharmacokinetic parameters derived from tests and population averages. These parameters are then tailored to patient-specific variables such as diagnosis, demographics, and allergy status. Once therapy commences, therapeutic response monitoring is critical and achieved through clinical and physical...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Meal-derived glucagon responses are related to lower hepatic phosphate concentrations in obesity and type 2 diabetes.

Diabetes & metabolism·2018

Same author

Inverse association of insulin antibody levels with insulin sensitivity in adults with Type 1 diabetes.

Diabetic medicine : a journal of the British Diabetic Association·2018

Same author

Optimal designs for active controlled dose-finding trials with efficacy-toxicity outcomes.

Biometrika·2018

Same author

Advanced Methods for Dose and Regimen Finding During Drug Development: Summary of the EMA/EFPIA Workshop on Dose Finding (London 4-5 December 2014).

CPT: pharmacometrics & systems pharmacology·2017

Same author

Circulating adiponectin concentration is inversely associated with glucose tolerance and insulin secretion in people with newly diagnosed diabetes.

Diabetic medicine : a journal of the British Diabetic Association·2016

Same author

"Threshold-crossing": A Useful Way to Establish the Counterfactual in Clinical Trials?

Clinical pharmacology and therapeutics·2016

Search research articles

Related Experiment Video

Updated: Jul 15, 2026

Using a Comparative Species Approach to Investigate the Neurobiology of Paternal Responses

Using a Comparative Species Approach to Investigate the Neurobiology of Paternal Responses

Published on: September 19, 2011

Ordered multiple comparisons with the best and their applications to dose-response studies.

K Strassburger¹, F Bretz, H Finner

¹German Diabetes Center, Leibniz Center at Heinrich-Heine-University Düsseldorf, Institute of Biometrics and Epidemiology, Düsseldorf, Germany. strass@ddz.uni-duesseldorf.de

|May 11, 2007

Summary

This study introduces a new method for comparing multiple ordered treatments to find the best one. It provides a statistically sound way to identify treatments that are significantly less effective than the top performer, ensuring reliable comparisons in research.

More Related Videos

Stepwise Dosing Protocol for Increased Throughput in Label-Free Impedance-Based GPCR Assays

Stepwise Dosing Protocol for Increased Throughput in Label-Free Impedance-Based GPCR Assays

Published on: February 21, 2020

Diagonal Method to Measure Synergy Among Any Number of Drugs

Diagonal Method to Measure Synergy Among Any Number of Drugs

Published on: June 21, 2018

Related Experiment Videos

Last Updated: Jul 15, 2026

Using a Comparative Species Approach to Investigate the Neurobiology of Paternal Responses

Using a Comparative Species Approach to Investigate the Neurobiology of Paternal Responses

Published on: September 19, 2011

Stepwise Dosing Protocol for Increased Throughput in Label-Free Impedance-Based GPCR Assays

Stepwise Dosing Protocol for Increased Throughput in Label-Free Impedance-Based GPCR Assays

Published on: February 21, 2020

Diagonal Method to Measure Synergy Among Any Number of Drugs

Diagonal Method to Measure Synergy Among Any Number of Drugs

Published on: June 21, 2018

Area of Science:

Biostatistics
Clinical Trial Design
Statistical Inference

Background:

Comparing multiple treatments to identify the most effective one is a common challenge in scientific research.
Treatments are often naturally ordered by risk or efficacy, such as dose levels in pharmaceutical studies.
Existing methods may not provide sufficiently sharp confidence bounds for identifying suboptimal treatments.

Purpose of the Study:

To develop a statistically rigorous method for comparing ordered treatments against the unknown best treatment.
To construct a lower confidence bound that identifies treatments significantly less effective than the top performer.
To provide tools for power and sample size calculations in such comparative studies.

Main Methods:

Development of a novel multiple testing strategy to achieve sharp confidence bounds.
Derivation of closed-form expressions for power and sample size calculations.
Application and validation of the proposed methods on real-world datasets.

Main Results:

A new multiple testing strategy yields sharp lower confidence bounds for treatment comparison.
The proposed method effectively identifies treatments that are marginally less effective than the best.
Closed-form solutions for power and sample size calculations are derived, facilitating study planning.

Conclusions:

The developed method offers a robust approach for comparing ordered treatments and identifying the best.
The derived confidence bounds ensure that less effective treatments are reliably distinguished from the optimal one.
This methodology has practical applications in various fields, including dose-response studies and intervention comparisons.